is it okay to switch from semaglutide to tirzepatide Switching between weight-loss medications 🥇 Switching from Semaglutide to

A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice The study examines the effectiveness of novel peptides that are a combination of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon

As off-label use continues to expand, particularly among patients with obesity or insulin resistance, our findings suggest GLP-1based therapies may warrant consideration as an adjunct to insulin in carefully selected patients. Advertisement Advertisement New service for patients with diabetes will make annual screening more convenient Association revises criteria for the diagnosis and resolution of severe conditions What to consider in the management of euglycemic DKA Less than 50% of patients with diabetes get appropriate ophthalmic screening through primary care referrals Familiarity will enhance its accessibility for patients with diabetes New study counters earlier findings linking drugs with eye disease Study highlights the value of quantitative ultra-widefield angiography Longevity in healthcare, personal experiences may provide caregivers with false sense of confidence

It works by activating two hormones in the body: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)

& Hay, N